EFFECT OF STATIN THERAPY ON LIVER FIBROSIS AND ITS ASSESSMENT IN PATIENTS WITH CHRONIC NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT ATHEROSCLEROSIS
Kurbonov Hayitjon Shavkat ugli
Asia International University, Bukhara, Uzbekistan
hayitjonshavkatovich@gmail.com
https://orcid.org/0009-0004-1827-4859
Background: Non-alcoholic fatty liver disease (NAFLD), now commonly classified within metabolic dysfunction-associated steatotic liver disease (MASLD), frequently coexists with dyslipidemia and atherosclerotic cardiovascular disease. Fibrosis stage is a major determinant of liver-related prognosis, whereas cardiovascular disease remains a major source of morbidity and mortality. Statins are fundamental for prevention of ASCVD events, yet concerns about hepatotoxicity have historically contributed to undertreatment, while experimental and observational data have raised the separate possibility that statins may attenuate hepatic fibrogenesis. [7]
Objective: To evaluate the effects of statin therapy on liver-fibrosis progression and regression in patients with NAFLD/NASH and concomitant atherosclerosis, while synthesizing evidence on mechanisms, cardiovascular outcomes, hepatic safety and the optimal methods for measuring fibrosis change.
Methods: A narrative, non-systematic review was conducted with priority given to literature from approximately September 2016 through September 2026 and to seminal older studies. PubMed/MEDLINE, the Cochrane evidence base, major AASLD, EASL-EASD-EASO and ESC/EAS guidance, and clinical-trial registry information were searched for randomized trials, cohort and case-control studies, systematic reviews/meta-analyses, diagnostic-accuracy studies and mechanistic research. English-language evidence was prioritized, with relevant Russian and Uzbekistan-origin literature considered. No original pooled effect was calculated.
Results: Human observational evidence generally associates statin exposure with less advanced fibrosis or slower progression. In a biopsy-based multicenter cohort, statin use was associated with lower odds of F2–F4 fibrosis (adjusted OR 0.42, 95% CI 0.20–0.80). A nationwide Korean analysis reported an adjusted OR of 0.43 for a BARD-defined significant-fibrosis endpoint. A primary-care cohort found a hazard ratio of 0.60 for progression to FIB-4 ≥2.67. Most importantly for longitudinal imaging, a 16-center cohort of 7,988 patients with steatotic liver disease found statin exposure associated with less liver-stiffness progression both with and without compensated advanced chronic liver disease, but not with significantly more liver-stiffness regression. Meta-analysis has reported lower odds of “significant fibrosis,” but with very high heterogeneity, while the pooled change in fibrosis stage itself was not significant. A short randomized trial containing a rosuvastatin arm showed no significant MRE fibrosis change over 24 weeks. These data support a potential progression-preventing effect more strongly than true regression. [8]
Conclusions: Statins are appropriate and generally safe for ASCVD prevention in patients with NAFLD/MASLD, including compensated advanced liver disease when otherwise clinically indicated. Current evidence does not establish statins as an approved or proven antifibrotic treatment. Evidence is strongest for an association with slower fibrosis/liver-disease progression, whereas convincing demonstration of fibrosis regression remains lacking. Serial assessment should use a multimodal strategy: FIB-4 for triage, VCTE and/or ELF for secondary evaluation, and MRE or biopsy when greater precision is required. Because statins can alter aminotransferases, changes in FIB-4 alone should not be interpreted as proof of collagen regression. [9]
Keywords: statins; non-alcoholic fatty liver disease; NAFLD; non-alcoholic steatohepatitis; NASH; MASLD; MASH; liver fibrosis; atherosclerosis; cardiovascular disease; FIB-4; elastography; magnetic resonance elastography; liver biopsy.
Introduction
NAFLD/NASH is closely linked to obesity, insulin resistance, type 2 diabetes, atherogenic dyslipidemia and ASCVD. Contemporary nomenclature defines MASLD as steatotic liver disease occurring with cardiometabolic risk factors and distinguishes the inflammatory form as MASH; the older NAFLD/NASH terminology remains embedded in most pivotal statin studies and is therefore retained when describing them. Fibrosis is the central liver-related prognostic variable: progression from mild fibrosis to bridging fibrosis and cirrhosis is associated with escalating risks of decompensation, hepatocellular carcinoma and liver-related death. [1]At the same time, treating ASCVD risk is indispensable. Current European lipid guidance continues to place statin-based LDL-C lowering at the center of risk-based prevention, particularly in patients with established atherosclerotic disease. In a patient who has both NAFLD/MASH and coronary, cerebrovascular or peripheral atherosclerosis, the relevant therapeutic question is therefore not merely whether statins change hepatic enzymes: it is whether cardiovascular benefit can be obtained safely while liver fibrosis is monitored appropriately, and whether the treatment may additionally influence the natural history of liver fibrosis. [1–3] [10]Historically, statin treatment was sometimes withheld when alanine aminotransferase (ALT) or aspartate aminotransferase (AST) was elevated. This approach is increasingly inconsistent with evidence. AASLD guidance identifies statins as safe for cardiovascular risk reduction in NAFLD, and a systematic review of 22 studies involving 2,345 NAFLD patients reported reductions rather than deterioration in ALT, AST and γ-glutamyl transferase after statin treatment. Contemporary randomized safety evidence across the much broader statin-treated population further supports a favorable benefit–risk profile. [1,13,18] [11]The more uncertain question is whether inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase changes fibrosis itself. Several biological mechanisms make such an effect plausible. Inhibition of the mevalonate pathway affects not only cholesterol synthesis but also production of isoprenoid intermediates required for prenylation of signaling molecules such as Rho family GTPases. Experimental work has linked statin exposure to reduced RhoA/Rho-kinase signaling, enhanced endothelial nitric-oxide synthase activity, induction of Kruppel-like factor 2 (KLF2), improved sinusoidal endothelial function and paracrine deactivation of hepatic stellate cells. These effects could theoretically reduce stellate-cell activation, extracellular-matrix deposition, inflammation and intrahepatic vascular resistance. [19,20] [12]Human clinical evidence, however, is methodologically more difficult. Statins are prescribed preferentially to patients with diabetes, dyslipidemia and ASCVD—features that themselves correlate with more severe MASLD. This creates confounding by indication. Conversely, statin users may receive more intensive medical surveillance and better cardiometabolic care, creating a “healthy-user” or care-intensity effect. Different studies have defined fibrosis using biopsy, BARD, FIB-4, elastography or clinical outcomes, so apparently similar endpoints are not necessarily equivalent. [13] A particularly important measurement issue is that some commonly used noninvasive fibrosis scores contain variables that statins can change independently of fibrosis. FIB-4 incorporates AST and ALT together with age and platelet count. Because statin therapy in NAFLD has repeatedly been associated with reductions in aminotransferase concentrations, a fall in FIB-4 during treatment may partly represent improvement in hepatocellular injury rather than remodeling of collagen. This is an inference from the structure of FIB-4 and the biochemical effects of statins, not proof that reported FIB-4 associations are spurious; it does, however, mean that biochemical scores should not be used alone to claim antifibrotic efficacy. [14] The purpose of this review is therefore to separate four different outcomes that are often conflated: lowering LDL-C and preventing ASCVD events; improving serum liver enzymes; preventing progression to more advanced fibrosis; and producing genuine regression of established fibrosis. These endpoints have different evidentiary standards and should not be treated as interchangeable.
Mechanistic basis for a possible antifibrotic effect. Statins inhibit HMG-CoA reductase and reduce mevalonate production. The downstream consequence is not limited to lower hepatic cholesterol synthesis; reduced generation of farnesyl and geranylgeranyl intermediates can alter prenylation-dependent signaling. Experimental cirrhosis models indicate that atorvastatin can suppress RhoA/Rho-kinase activity and improve endothelial nitric-oxide signaling, while work in sinusoidal endothelial cells has demonstrated KLF2-dependent endothelial protection and paracrine deactivation of hepatic stellate cells after statin exposure. Because activated stellate cells are central producers of extracellular matrix during hepatic fibrogenesis, these mechanisms provide a credible biological pathway from statin exposure to reduced fibrogenic activity. [19,20] [12]
A second plausible pathway is reduction of hepatic cholesterol-related lipotoxicity and inflammatory signaling. In the biopsy cohort of Dongiovanni and colleagues, the biological hypothesis was that excess hepatic free cholesterol contributes to NASH pathogenesis; statin exposure was associated not only with less advanced fibrosis but also with lower prevalence of steatosis and steatohepatitis. Genetic heterogeneity may modify this relationship: the PNPLA3 I148M variant attenuated some of the observed association with steatohepatitis, illustrating why a uniform hepatic response to statins should not be assumed. [4] [17]
These mechanisms remain supportive rather than determinative. A pharmacological pathway can explain why a clinical effect might occur, but it cannot establish that established human fibrosis regresses. That question requires longitudinal human measurements with adequate controls.
Clinical evidence for fibrosis progression and regression. One of the earliest human histological observations came from Ekstedt and colleagues. Sixty-eight NAFLD patients underwent repeat liver biopsy after approximately 10.3–16.3 years; 17 were receiving statins at follow-up. Despite having a metabolically higher-risk phenotype, statin-treated patients showed reduced steatosis, and only four progressed in fibrosis stage. The study was small and nonrandomized and does not establish causality, but it was important in demonstrating that long-term statin exposure in NAFLD was not accompanied by obvious histological liver toxicity. [5] [18]
Dongiovanni et al. subsequently analyzed 1,201 European patients who underwent liver biopsy for suspected NASH. Statins were used by 107 patients. In propensity-matched analysis, exposure was associated with lower odds of steatosis (OR 0.09), NASH (OR 0.25) and F2–F4 fibrosis (OR 0.42, 95% CI 0.20–0.80). A dose-dependent association was reported. The use of histology is an important strength, but the design was observational and largely cross-sectional with respect to the fibrosis endpoint; therefore the result is evidence of an association with less severe histological disease, not direct demonstration that statins reversed pre-existing fibrosis. [4] [17]
A nationwide Korean study substantially expanded statistical power. Among more than 11 million participants, investigators constructed a NAFLD cohort using the fatty liver index and defined significant fibrosis using BARD ≥2. Among 712,262 subjects classified as having NAFLD, statin use was associated with lower odds of the fibrosis endpoint (adjusted OR 0.43, 95% CI 0.42–0.44), including analyses stratified by diabetes. The scale and adjustment are strengths, but neither NAFLD nor fibrosis was determined histologically, and BARD is a surrogate score influenced by metabolic and biochemical variables. [6] [19]
A 2024 primary-care MASLD cohort provided longitudinal evidence. Among 1,238 patients initially below the high-risk FIB-4 threshold, 47% received a statin and 18% progressed to FIB-4 ≥2.67 over mean follow-up of 3.3 years. Statin prescription was associated with a lower adjusted risk of progression (HR 0.60, 95% CI 0.45–0.80), with similar estimates for moderate- and high-intensity therapy. This supports prevention of progression in a real-world setting but shares the fundamental limitation that FIB-4 is partly determined by aminotransferase concentrations. [7] [20]
The strongest large-scale longitudinal elastography evidence is the international VCTE-Prognosis cohort published in Gut. It included 7,988 patients with MASLD from 16 tertiary centers, 40.5% of whom were using statins, and followed them for a median of 4.6 years. Statin use was associated with less liver-stiffness progression in patients with compensated advanced chronic liver disease (adjusted HR approximately 0.54) and without it (adjusted HR approximately 0.45). Importantly, however, statin use was not significantly associated with liver-stiffness regression (adjusted HR 0.914, 95% CI 0.778–1.074). The same study reported lower liver-related clinical-event and all-cause mortality risks among statin users. This distinction—less progression without demonstrably more regression—is highly relevant to interpretation of the total evidence. [8] [21]
A Swedish histopathology-linked cohort provides complementary outcome evidence. Among matched statin users and nonusers with noncirrhotic chronic liver disease, statin exposure was associated with a lower risk of severe liver disease overall (HR 0.60). In the NAFLD subgroup the estimate was HR 0.68 (95% CI 0.45–1.00), and statin exposure was also associated with lower progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in the overall chronic-liver-disease cohort. These outcomes strengthen the possibility of disease modification but still do not prove histological fibrosis regression. [9] [22]
Not all observational analyses are positive. A propensity-score-matched study among US veterans with diabetes matched 34,102 statin users with 34,102 nonusers and found a composite NAFLD-progression endpoint in 8.8% versus 8.6% (OR 1.02, 95% CI 0.97–1.08), indicating no statistically significant overall association. A post-hoc comparison suggested more recorded progression with more intensive LDL-C reduction, but the nonrandomized design, composite coding-based outcome and possibility of residual confounding preclude interpreting that finding as evidence that intensive statin therapy causes fibrosis. [10] [23]
Meta-analytic findings reflect the same uncertainty. Fatima et al. synthesized 14 studies totaling approximately 1.25 million participants and reported lower odds of “significant fibrosis” among statin users (OR 0.20), but heterogeneity for this endpoint was extremely high (I² 97%). More tellingly, the pooled change in fibrosis stage was not significant (WMD 0.07, 95% CI −0.05 to 0.20). Improvements were clearer for liver enzymes, steatosis and NAFLD activity score than for established fibrosis. [11] [24]
A separate 2022 meta-analysis likewise found improvements in biochemical parameters, steatosis grade and NAFLD activity score, but methodological heterogeneity was high. More recent synthesis through 2025 continues to support improvements in aminotransferases and lipids while leaving direct antifibrotic efficacy less certain. [12,17] [25]
Randomized evidence remains a major weakness. The older Cochrane review identified only very limited, high-risk-of-bias randomized evidence and could not establish histological benefit. In the ESSENTIAL randomized trial, 70 NAFLD patients received rosuvastatin 5 mg either alone or combined with ezetimibe for 24 weeks. Both groups showed reduced MRI-measured liver fat, but MRE-derived fibrosis change was not significant. Because both groups received rosuvastatin, the trial cannot estimate statin-versus-placebo antifibrotic efficacy, and 24 weeks is short for observing meaningful collagen remodeling. [14,16] [26]
A dedicated phase-2 atorvastatin study in NASH with significant fibrosis has also been registered, using histologically relevant improvement criteria. This ongoing evidence gap is important: the central antifibrotic hypothesis is still awaiting a properly powered randomized answer rather than merely another observational association. [27]
1. Rinella M. E., Neuschwander-Tetri B. A., Siddiqui M. S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. — 2023. — Vol. 77, no. 5. — P. 1797–1835. — DOI: 10.1097/HEP.0000000000000323. [52]
2. European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) // Journal of Hepatology. — 2024. — Vol. 81, no. 3. — P. 492–542. — DOI: 10.1016/j.jhep.2024.04.031. [53]
3. Mach F., Koskinas K. C., Roeters van Lennep J. E. et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias // European Heart Journal. — 2025. — Vol. 46, no. 42. — P. 4359–4378. — DOI: 10.1093/eurheartj/ehaf190. [32]
4. Dongiovanni P., Petta S., Männistö V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals // Journal of Hepatology. — 2015. — Vol. 63, no. 3. — P. 705–712. — DOI: 10.1016/j.jhep.2015.05.006. [17]
5. Ekstedt M., Franzén L. E., Mathiesen U. L. et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study // Journal of Hepatology. — 2007. — Vol. 47, no. 1. — P. 135–141. — DOI: 10.1016/j.jhep.2007.02.013. [18]
6. Lee J. I., Lee H. W., Lee K. S., Lee H. S., Park J. Y. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study // American Journal of Gastroenterology. — 2021. — Vol. 116, no. 1. — P. 116–124. — DOI: 10.14309/ajg.0000000000000845. [19]
7. Schreiner A. D., Zhang J., Petz C. A. et al. Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD // BMJ Open Gastroenterology. — 2024. — Vol. 11, no. 1. — e001404. — DOI: 10.1136/bmjgast-2024-001404. [20]
8. Zhou X.-D., Kim S. U., Yip T. C.-F. et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease // Gut. — 2024. — Vol. 73, no. 11. — P. 1883–1892. — DOI: 10.1136/gutjnl-2024-333074. [54]
9. Sharma R., Simon T. G., Hagström H. et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease // Clinical Gastroenterology and Hepatology. — 2024. — Vol. 22, no. 4. — P. 749–759.e19. — DOI: 10.1016/j.cgh.2023.04.017. [22]
10. Shah R., Kong A., De Melo S. et al. Association of statins with nonalcoholic fatty liver disease in patients with diabetes // Journal of Investigative Medicine. — 2024. — Vol. 72, no. 6. — P. 497–510. — DOI: 10.1177/10815589241248076. [23]
11. Fatima K., Moeed A., Waqar E. et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis // Clinics and Research in Hepatology and Gastroenterology. — 2022. — Vol. 46, no. 4. — 101816. — DOI: 10.1016/j.clinre.2021.101816. [24]
12. Boutari C. et al. Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis // Clinical Nutrition. — 2022. — Vol. 41, no. 10. — P. 2195–2206. — DOI: 10.1016/j.clnu.2022.08.001. [55]
13. Pastori D., Pani A., Di Rocco A. et al. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis // British Journal of Clinical Pharmacology. — 2022. — Vol. 88, no. 2. — P. 441–451. — DOI: 10.1111/bcp.14943. [33]
14. Eslami L., Merat S., Malekzadeh R., Nasseri-Moghaddam S., Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis // Cochrane Database of Systematic Reviews. — 2013. — Issue 12. — CD008623. — DOI: 10.1002/14651858.CD008623.pub2.
15. Athyros V. G., Tziomalos K., Gossios T. D. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis // The Lancet. — 2010. — Vol. 376, no. 9756. — P. 1916–1922. — DOI: 10.1016/S0140-6736(10)61272-X. [28]
16. Cho Y., Rhee H., Kim Y.-E. et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study) // BMC Medicine. — 2022. — Vol. 20. — Article 93. — DOI: 10.1186/s12916-022-02288-2. [56]
17. Fang X., Yin Y., Wu Q. et al. Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis // Expert Review of Clinical Pharmacology. — 2025. — Vol. 18, no. 12. — P. 1095–1106. — DOI: 10.1080/17512433.2025.2600410. [57]
18. Cholesterol Treatment Trialists' (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials // The Lancet. — 2026. — Vol. 407, no. 10529. — P. 689–703. — DOI: 10.1016/S0140-6736(25)01578-8. [34]
19. Trebicka J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase // Hepatology. — 2007. — Vol. 46. — P. 242–253. — DOI: 10.1002/hep.21673.
20. Marrone G. et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins // Journal of Hepatology. — 2013. — Vol. 58, no. 1. — P. 98–103. — DOI: 10.1016/j.jhep.2012.08.026. [12]
21. Han S., Choi M., Lee B. et al. Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis // Gut and Liver. — 2022. — Vol. 16, no. 6. — P. 952–963. — DOI: 10.5009/gnl210391. [37]
22. Selvaraj E. A., Mózes F. E., Jayaswal A. N. A. et al.; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis // Journal of Hepatology. — 2021. — Vol. 75, no. 4. — P. 770–785. — DOI: 10.1016/j.jhep.2021.04.044. [39]
23. Loomba R. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study // Hepatology. — 2014. — Vol. 60. — P. 1919–1927. — DOI: 10.1002/hep.27362.
24. Ratziu V., Charlotte F., Heurtier A. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease // Gastroenterology. — 2005. — Vol. 128, no. 7. — P. 1898–1906. — DOI: 10.1053/j.gastro.2005.03.084.
25. Kronborg T. M., Schierwagen R., Trošt K. et al. Atorvastatin for patients with cirrhosis: a randomized, placebo-controlled trial // Hepatology Communications. — 2023. — Vol. 7, no. 12. — e0332. — DOI: 10.1097/HC9.0000000000000332. [35]
26. Lazebnik L. B., Golovanova E. V., Turkina S. V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version [in Russian] // Experimental and Clinical Gastroenterology. — 2021. — Vol. 185, no. 1. — P. 4–52. — DOI: 10.31146/1682-8658-ecg-185-1-4-52. [58]
27. Sadikova D. Sh., Khaydarova F., Esimova D. M. Construction of computer model for diagnostics and monitoring of non-alcoholic fatty liver disease // Uzbek Medical Journal. — 2021. — Vol. 2, no. 2. — P. 9–14. — DOI: 10.26739/2181-0664-2021-2-2. [59]
28. ClinicalTrials.gov. Study of atorvastatin therapy in patients with nonalcoholic steatohepatitis and significant fibrosis. — Clinical trial registry record NCT04679376. — DOI: not applicable to the registry record. Status and completion information should be rechecked before publication of the final manuscript because the study remained within its reported trial timeline at the September 13, 2026 literature cutoff. [27]